Trial Profile
A randomized, multicenter, open-label, active-controlled, single-dose, 5-period, incomplete block, cross-over study to evaluate the relative bronchodilating effects of formoterol when administered via Symbicort [budesonide/formoterol] pMDI [pressurized metered-dose inhaler] or Oxis Turbuhaler [formoterol] to adults with stable asthma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Budesonide/formoterol (Primary) ; Formoterol
- Indications Asthma
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 06 May 2008 New trial record.